Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10

Targeted inhibition of Rho-associated kinase (ROCK)2 downregulates the proinflammatory T cell response while increasing the regulatory arm of the immune response in animals models of autoimmunity and Th17-skewing human cell culture in vitro. In this study, we report that oral administration of a sel...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunol
Autori principali: Zanin-Zhorov, Alexandra, Weiss, Jonathan M., Trzeciak, Alissa, Chen, Wei, Zhang, Jingya, Nyuydzefe, Melanie S., Arencibia, Carmen, Polimera, Seetharam, Schueller, Olivier, Fuentes-Duculan, Judilyn, Bonifacio, Kathleen M., Kunjravia, Norma, Cueto, Inna, Soung, Jennifer, Fleischmann, Roy M., Kivitz, Alan, Lebwohl, Mark, Nunez, Margarita, Woodson, Johnnie, Smith, Shondra L., West, Robert F., Berger, Mark, Krueger, James G., Ryan, John L., Waksal, Samuel D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AAI 2017
Soggetti:
Cutting Edge
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5421306/
https://ncbi.nlm.nih.gov/pubmed/28389592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1602142
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi